BCMU
FLNA

BlueCrest Capital Management (UK)’s Filana Therapeutics FLNA Stock Holding History

BlueCrest Capital Management (UK)’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-7,543
Closed -$290K – 704
2014
Q1 		$290K Buy
+7,543
New +$266K 0.02% 422

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
MSP
Madison Street Partners Denver, Colorado $3.05M AUM 5.94% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlueCrest Capital Management (UK)'s FLNA Position: Q2 2014 in Review

BlueCrest Capital Management (UK) sold out of Filana Therapeutics (FLNA) in Q2 2014, closing a stake of 7,543 shares — an estimated $290K sold.

BlueCrest Capital Management (UK) first reported a position in FLNA in Q1 2014 and held it in 1 quarter. The position peaked at $290K in Q1 2014. 87 funds tracked by Wall St. Rank hold FLNA as of Q2 2014.

  • BlueCrest Capital Management (UK) reported no remaining Filana Therapeutics position as of Q2 2014 after selling out during the quarter.
  • BlueCrest Capital Management (UK) sold 7,543 Filana Therapeutics shares in Q2 2014, an estimated $290K.
  • BlueCrest Capital Management (UK) first reported a position in Filana Therapeutics in Q1 2014 and held it in 1 quarter.
  • BlueCrest Capital Management (UK)'s Filana Therapeutics position peaked at $290K in Q1 2014.
  • 87 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2014.

Based on BlueCrest Capital Management (UK)'s 13F filing for Q2 2014, filed 15 Aug 2014.